Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 185

1.

Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality: A Cohort Study.

Muntner P, Whittle J, Lynch AI, Colantonio LD, Simpson LM, Einhorn PT, Levitan EB, Whelton PK, Cushman WC, Louis GT, Davis BR, Oparil S.

Ann Intern Med. 2015 Sep 1;163(5):329-338. doi: 10.7326/M14-2803.

PMID:
26215765
2.

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.

Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR; TECOS Study Group.

N Engl J Med. 2015 Jul 16;373(3):232-42. doi: 10.1056/NEJMoa1501352. Epub 2015 Jun 8. Erratum in: N Engl J Med. 2015 Aug 6;373(6):586.

PMID:
26052984
3.

Real-world evidence supports optimally dosed thiazide-type diuretics as preferred in treatment regimens of older adults with hypertension.

Einhorn PT, Whelton PK, Davis BR, Wright JT Jr, Cushman WC, Zieman SJ.

J Am Geriatr Soc. 2015 May;63(5):1045-7. doi: 10.1111/jgs.13415. No abstract available.

PMID:
25989579
4.

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.

Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Lam H, White WB; EXAMINE Investigators.

Lancet. 2015 May 23;385(9982):2067-76. doi: 10.1016/S0140-6736(14)62225-X. Epub 2015 Mar 10.

PMID:
25765696
5.

Systolic Blood Pressure Control Among Individuals With Type 2 Diabetes: A Comparative Effectiveness Analysis of Three Interventions.

Espeland MA, Probstfield J, Hire D, Redmon JB, Evans GW, Coday M, Lewis CE, Johnson KC, Wilmoth S, Bahnson J, Dulin MF, Green JB, Knowler WC, Kitabchi A, Murillo AL, Osei K, Rehman SU, Cushman WC; Look AHEAD Research Group; ACCORD Study Group.

Am J Hypertens. 2015 Aug;28(8):995-1009. doi: 10.1093/ajh/hpu292. Epub 2015 Feb 9.

PMID:
25666468
6.

Effects of medicare part d on disparity implications of medication therapy management eligibility criteria.

Wang J, Qiao Y, Shih YC, Jamison JJ, Spivey CA, Li L, Wan JY, White-Means SI, Dagogo-Jack S, Cushman WC, Chisholm-Burns M.

Am Health Drug Benefits. 2014 Sep;7(6):346-58.

7.

Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT.

Yamal JM, Oparil S, Davis BR, Alderman MH, Calhoun DA, Cushman WC, Fendley HF, Franklin SS, Habib GB, Pressel SL, Probstfield JL, Sastrasinh S; ALLHAT Collaborative Research Group.

J Am Soc Hypertens. 2014 Nov;8(11):808-19. doi: 10.1016/j.jash.2014.08.003. Epub 2014 Aug 19.

PMID:
25455006
8.

Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Muntner P, Davis BR, Cushman WC, Bangalore S, Calhoun DA, Pressel SL, Black HR, Kostis JB, Probstfield JL, Whelton PK, Rahman M; ALLHAT Collaborative Research Group.

Hypertension. 2014 Nov;64(5):1012-21. doi: 10.1161/HYPERTENSIONAHA.114.03850. Epub 2014 Aug 4.

PMID:
25259745
9.

Association of medical treatment nonadherence with all-cause mortality in newly treated hypertensive US veterans.

Gosmanova EO, Lu JL, Streja E, Cushman WC, Kalantar-Zadeh K, Kovesdy CP.

Hypertension. 2014 Nov;64(5):951-7. doi: 10.1161/HYPERTENSIONAHA.114.03805. Epub 2014 Aug 4.

PMID:
25259744
10.

Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes.

Papademetriou V, Lovato L, Doumas M, Nylen E, Mottl A, Cohen RM, Applegate WB, Puntakee Z, Yale JF, Cushman WC; ACCORD Study Group.

Kidney Int. 2015 Mar;87(3):649-59. doi: 10.1038/ki.2014.296. Epub 2014 Sep 17.

PMID:
25229335
11.

Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study).

Fatemi O, Yuriditsky E, Tsioufis C, Tsachris D, Morgan T, Basile J, Bigger T, Cushman W, Goff D, Soliman EZ, Thomas A, Papademetriou V.

Am J Cardiol. 2014 Oct 15;114(8):1217-22. doi: 10.1016/j.amjcard.2014.07.045. Epub 2014 Jul 30.

PMID:
25159234
12.

Potential effects of racial and ethnic disparities in meeting Medicare medication therapy management eligibility criteria.

Wang J, Qiao Y, Tina Shih YC, Spivey CA, Dagogo-Jack S, Wan JY, White-Means SI, Cushman WC, Chisholm-Burns MA.

J Pharm Health Serv Res. 2014 Jun;5(2):109-118.

13.

The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).

Ambrosius WT, Sink KM, Foy CG, Berlowitz DR, Cheung AK, Cushman WC, Fine LJ, Goff DC Jr, Johnson KC, Killeen AA, Lewis CE, Oparil S, Reboussin DM, Rocco MV, Snyder JK, Williamson JD, Wright JT Jr, Whelton PK; SPRINT Study Research Group.

Clin Trials. 2014 Oct;11(5):532-46. doi: 10.1177/1740774514537404. Epub 2014 Jun 5.

PMID:
24902920
14.

Proceedings from Duke resistant hypertension think tank.

Vemulapalli S, Ard J, Bakris GL, Bhatt DL, Brown AS, Cushman WC, Ferdinand KC, Flack JM, Fleg JL, Katzen BT, Kostis JB, Oparil S, Patel CB, Pepine CJ, PiƱa IL, Rocha-Singh KJ, Townsend RR, Peterson ED, Califf RM, Patel MR.

Am Heart J. 2014 Jun;167(6):775-88.e1. doi: 10.1016/j.ahj.2014.02.008. Epub 2014 Feb 28.

PMID:
24890525
15.

Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial.

Margolis KL, O'Connor PJ, Morgan TM, Buse JB, Cohen RM, Cushman WC, Cutler JA, Evans GW, Gerstein HC, Grimm RH Jr, Lipkin EW, Narayan KM, Riddle MC Jr, Sood A, Goff DC Jr.

Diabetes Care. 2014 Jun;37(6):1721-8. doi: 10.2337/dc13-2334. Epub 2014 Mar 4.

16.

2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).

James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E.

JAMA. 2014 Feb 5;311(5):507-20. doi: 10.1001/jama.2013.284427. Erratum in: JAMA. 2014 May 7;311(17):1809.

PMID:
24352797
17.

Chlorthalidone versus hydrochlorothiazide in hypertension treatment: do we have the evidence to decide?

Oparil S, Cushman WC, Lederle FA.

Am J Kidney Dis. 2014 Mar;63(3):387-9. doi: 10.1053/j.ajkd.2013.11.009. Epub 2013 Dec 11. No abstract available.

PMID:
24331977
18.

Inflammatory Pseudotumor Containing Kayexalate Crystals: A Case Report and Review of the Literature.

Romano RC, Thirumala S, Cushman WH, Mounajjed T.

Int J Surg Pathol. 2014 Aug;22(5):464-9. doi: 10.1177/1066896913507598. Epub 2013 Oct 31.

PMID:
24178951
19.

Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial.

Miller ME, Williamson JD, Gerstein HC, Byington RP, Cushman WC, Ginsberg HN, Ambrosius WT, Lovato L, Applegate WB; ACCORD Investigators.

Diabetes Care. 2014;37(3):634-43. doi: 10.2337/dc13-1545. Epub 2013 Oct 29.

20.

Blood pressure and mortality in U.S. veterans with chronic kidney disease: a cohort study.

Kovesdy CP, Bleyer AJ, Molnar MZ, Ma JZ, Sim JJ, Cushman WC, Quarles LD, Kalantar-Zadeh K.

Ann Intern Med. 2013 Aug 20;159(4):233-42. doi: 10.7326/0003-4819-159-4-201308200-00004.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk